Pioneering C1q inhibition to Treat Complement-Mediated Neurodegenerative Diseases

The complement pathway is an essential part of the immune system and is activated by distinct mechanisms via 3 main pathways: the classical, lectin, and alternative pathways[1-3]



Upstream C1q inhibition of the classical complement pathway potentially protects against synaptic loss[3-5]

- Blocks all components of the classical complement pathway, while preserving the protective activity of the lectin and alternative pathways
- Prevents downstream effects of the inflammatory cascade, including synapse elimination and neurodegeneration

C1q is a key inflammatory mediator in complement-mediated neurodegeneration[3,5-8]



References

1. Carpanini SM, et al. *Front Immunol*. 2019;10:362.
2. Dunkelberger JR, Song WC. *Cell Res*. 2010;20(1):34-50.
3. Data on file. Annexon, South San Francisco, CA.
4. Ricklin D, Lambris JD. *Semin Immunol*. 2016;28(3):208-222.
5. Cho K. *Aging Dis*. 2019;10(3):652-663.
6. Stevens B, et al. *Cell*. 2007;131(6):1164-1178.
7. Hajishengallis G, et al. *Nat Immunol*. 2017;18(12):1288-1298.
8. Presumey J, et al. *Adv Immunol*. 2017;135:53-79.

ANNEXON biosciences

Huntington's Disease Phase 2a Study

Pioneering C1q inhibition to Treat Complement-Mediated Neurodegenerative Diseases

Advancing classical complement pathway inhibitors in neurodegenerative diseases of the brain

THERAPY	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	CURRENTLY ENROLLING
ANX005 (IV)	Huntington's Disease (HD)					https://clinicaltrials.gov/ct2/show/NCT04514367
ANX005 (IV)	Amyotrophic Lateral Sclerosis (ALS)					https://clinicaltrials.gov/ct2/show/NCT04569435?term=annexon&draw=2&rank=5

If you are a healthcare provider, caregiver, or patient who is interested in enrolling in the ANX005 HD phase 2a study, please click on the links below to learn more:

https://clinicaltrials.gov/ct2/show/NCT04514367

https://hdsa.org/hd-research/hd-trial-finder/

ANX005-HD-01 phase 2a study in Huntington's disease

A biomarker-driven trial to assess safety, C1q target engagement and impact on neurodegeneration

Objective

To demonstrate that an anti-C1q approach with ANX005 can reduce neurodegeneration (neurofilament light chain [NfL] levels) in a chronic neurodegenerative disease, such as HD

Huntington's disease study centers

Partnering with key academic consortia and patient advocacy groups, including:

- Huntington Study Group
- Huntington's Disease Society of America
- Enroll-HD



US study sites

- Birmingham, Alabama
- Sacramento, California
- Englewood, Colorado
- Washington, District of Columbia
- Durham, North Carolina
- Cincinnati, Ohio
- Kirkland, Washington
- Spokane, Washington

Currently recruiting 24 participants

Study design

Open-label study with 7 infusions of intravenous ANX005:

- Induction dose (on day 1 and day 5/6)
- Followed by maintenance dosing every 2 weeks (weeks 2, 4, 6, 8, 10)
- Follow-up at weeks 12 and 16
- End of Study visit at week 24

Inclusion criteria

Participants with, or at risk for, manifest HD:

- Men or women ≥18 years old
- Total CAG-Age Product (CAP) score >400
- Unified Huntington's Disease Rating Scale (UHDRS) independence score ≥80%

Primary outcome measure

- Incidence of treatment-emergent adverse events

Secondary outcome measures

- Pharmacokinetics measured by ANX005 serum and cerebrospinal fluid concentrations
- Pharmacodynamics measured by C1q, C4a, and NfL blood and cerebrospinal fluid concentrations as biomarkers of target/pathway engagement and neurodegeneration